Prof Mohd Haris Siddiqui

Prof Mohd Haris Siddiqui


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2024 in Neuroscience
Verified
Journal Article
Closed access
SSSana Sarkar
Sana Sarkar
APAnuj Pandey
Anuj Pandey
SYSANJEEV KUMAR YADAV
SANJEEV KUMAR YADAV
PSProf Mohd Haris Siddiqui
Prof Mohd Haris Siddiqui
APAditya Bhushan Pant
Aditya Bhushan Pant
SYSANJEEV KUMAR YADAV
SANJEEV KUMAR YADAV

8 October 2026 in Biomolecules
Verified
Journal Article
Open access
PDF file
SKShahper KHAN
Shahper KHAN
D.Danishuddin ....
Danishuddin ....
SISalamatu Tijjani Isah
Salamatu Tijjani Isah
PSProf Mohd Haris Siddiqui
Prof Mohd Haris Siddiqui
AAAamir Ahmad
Aamir Ahmad
JKJong-Joo Kim
Jong-Joo Kim
Clinical heterogeneity remains a major challenge across human diseases, where patients with similar genetic backgrounds frequently exhibit striking differences in disease progression, therapeutic response and clinical outcome. Increasing evidence indicates that these differences cannot be explained by genetic variation alone, positioning epigenetic memory as a critical non-genetic determinant of disease behavior. Epigenetic memory refers to the stable yet reversible propagation of transcriptional states through mechanisms including DNA methylation, histone modifications, chromatin accessibility, enhancer dynamics and higher-order chromatin organization. In this review, we synthesize emerging mechanistic and translational evidence demonstrating how epigenetic memory integrates environmental, metabolic, inflammatory, infectious and therapeutic cues into persistent cellular programs that drive inter-patient, intra-tumoral and temporal heterogeneity. We discuss its disease-specific manifestations across cancer, immunological, neurological, and metabolic disorders, with particular emphasis on cellular plasticity, stemness, immune evasion, drug-tolerant persister states and relapse. Furthermore, we highlight recent advances in single-cell and spatial epigenomics, liquid-biopsy-based epigenetic biomarkers, CRISPR-mediated epigenome editing and targeted chromatin therapies that collectively establish epigenetic memory as both a measurable biomarker and a therapeutically actionable vulnerability. By framing epigenetic memory as a dynamic interface between genome and environment, this review provides a unified conceptual framework for understanding disease evolution and advancing precision epigenetic medicine.